Phase I Trial of Intra-arterial Administration of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Patients with Multiple System Atrophy.

Compared to the low-dose group, the medium- and high-dose groups appeared to have a slower rate of increase in UMSARS Part II score (group × time, p = 0.131) and total UMSARS score (group × time, p = 0.096), which did not reach statistical significance because each treatment group contained only a small number of patients ( Table 3 ). 3.4.

also in 111,027 other papers